- Home
- CRIS vs ICU Comparison
CRIS vs ICU Comparison
Compare CRIS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ICU
- Stock Information
- Founded
- CRIS 2000
- ICU 2018
- Country
- CRIS United States
- ICU United States
- Employees
- CRIS N/A
- ICU N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- ICU Health Care
- Exchange
- CRIS Nasdaq
- ICU Nasdaq
- Market Cap
- CRIS 22.9M
- ICU 25.6M
- IPO Year
- CRIS 2000
- ICU N/A
- Fundamental
- Price
- CRIS $1.65
- ICU $0.65
- Analyst Decision
- CRIS Strong Buy
- ICU
- Analyst Count
- CRIS 2
- ICU 0
- Target Price
- CRIS $16.50
- ICU N/A
- AVG Volume (30 Days)
- CRIS 66.6K
- ICU 3.8M
- Earning Date
- CRIS 11-13-2025
- ICU 11-12-2025
- Dividend Yield
- CRIS N/A
- ICU N/A
- EPS Growth
- CRIS N/A
- ICU N/A
- EPS
- CRIS N/A
- ICU N/A
- Revenue
- CRIS $11,405,000.00
- ICU $766,000.00
- Revenue This Year
- CRIS $2.72
- ICU $820.00
- Revenue Next Year
- CRIS $8.27
- ICU $63.37
- P/E Ratio
- CRIS N/A
- ICU N/A
- Revenue Growth
- CRIS 12.24
- ICU N/A
- 52 Week Low
- CRIS $1.02
- ICU $0.31
- 52 Week High
- CRIS $5.51
- ICU $4.28
- Technical
- Relative Strength Index (RSI)
- CRIS 42.93
- ICU 42.56
- Support Level
- CRIS $1.58
- ICU $0.62
- Resistance Level
- CRIS $1.74
- ICU $0.72
- Average True Range (ATR)
- CRIS 0.09
- ICU 0.09
- MACD
- CRIS -0.00
- ICU -0.03
- Stochastic Oscillator
- CRIS 17.34
- ICU 14.93
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.